サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：頭頸部がんの世界市場の評価：治療タイプ別、投与経路別、薬剤クラス別、販売チャネル別、地域別、機会、予測（2017年～2031年）
市場調査レポート
商品コード
1417591

頭頸部がんの世界市場の評価：治療タイプ別、投与経路別、薬剤クラス別、販売チャネル別、地域別、機会、予測（2017年～2031年）

Head and Neck Cancer Market Assessment, By Therapy Type By Route of Administration, By Drug Class, By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 244 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
頭頸部がんの世界市場の評価：治療タイプ別、投与経路別、薬剤クラス別、販売チャネル別、地域別、機会、予測（2017年～2031年）
出版日: 2024年01月29日
発行: Market Xcel - Markets and Data
ページ情報: 英文 244 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の頭頸部がんの市場規模は2023年に22億5,000万米ドル、2031年に37億6,000万米ドルに達し、2024年～2031年の予測期間にCAGRで6.62%の成長が見込まれています。疾患と治療法の理解が進むにつれて、市場は大きな成長と進化を示しています。

頭頸部がんは、口腔、咽頭、喉頭などに発生する腫瘍を含み、世界的に大きな医療負担となっています。タバコやアルコールの摂取、ヒトパピローマウイルス（HPV）感染、環境要因などの危険因子が、これらのがんの発症に寄与しています。世界の頭頸部がん市場は、罹患率の増加、診断方法の改善、革新的な治療アプローチの開発などの要因によって牽引されています。近年の免疫療法や標的療法の進歩は患者に希望をもたらしています。これらの新たな治療法は、精密医療や個別化治療計画への注目の高まりとともに、市場に変革をもたらしつつあります。市場の主要企業は、新たな治療法を導入し、製品ポートフォリオを拡大するために研究開発に投資しています。さらに、早期発見と予防の重要性に対する意識の高まりも、市場の成長に寄与しています。世界の頭頸部がん市場はダイナミックで急速に発展しており、先進の治療オプションと早期介入戦略を通じて患者の転帰を改善することに注力しています。

免疫療法における新しい治療法

Elsevierが発表した記事によると、免疫療法の導入が頭頸部がんの治療に顕著な変革をもたらしたと報告されています。これらの治療法は、腫瘍細胞とTリンパ球の相互作用を媒介する免疫抑制経路を調節することに主眼が置かれています。2022年8月にFrontiersに発表された記事では、特に頭頸部扁平上皮がんの治療において、免疫療法が持続的な抗腫瘍効果をもたらす大きな可能性が示されています。共刺激アゴニスト、免疫チェックポイント阻害薬、抗原ワクチン、養子T細胞移植（ACT）、オンコリティックウイルス療法、EGFR標的療法などのさまざまな免疫療法アプローチが頭頸部扁平上皮がん（HNSCC）の治療に用いられています。例えば、Merckは2023年11月、FDAがMerckの抗PD-1療法であるキイトルーダを、ゲムシタビンとシスプラチンとともに、局所進行切除不能または転移性の胆道がん（BTC）向けの治療薬として承認したと発表しました。

研究開発への多大な投資

近年、世界の頭頸部がんに関連する研究開発活動が急増しています。このような注目の高まりは複数の要因に起因しています。例えば、世界の頭頸部がんの罹患率の上昇により、予防、早期発見、治療戦略に関するより包括的な研究の必要性が高まっています。また、ゲノミクスや標的療法を含む医療技術の進歩により、個別化されたより効果的な治療への新たな道が開かれました。

例えば、臨床開発後期のバイオテクノロジー企業であるNanobiotixは、2023年10月、NBTXR3の安全性と有効性を検証するフェーズ3臨床試験であるNANORAY-312の患者登録開始を発表しました。この薬剤候補は、高齢者の頭頸部がんの効果的な治療において大きな可能性を示しています。2022年9月、免疫療法の開発とマーケティングに特化した臨床段階にあるバイオテクノロジー企業Genexine Inc.は、フェーズ2臨床試験の患者投与開始を発表しました。GX-188E（治療用DNAワクチン）、GX-I7（長時間作用型インターロイキン7）、OpdivoR（ニボルマブ）、PD-1免疫チェックポイント阻害薬を含む3剤併用療法を採用し、転移性または再発性の頭頸部扁平上皮がんに対処します。

当レポートでは、世界の頭頸部がん市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界の頭頸部がん市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界の頭頸部がん市場の見通し（2017年～2031年）

  • 市場規模と予測
    • 金額
    • 数量
  • 治療タイプ別
    • 化学療法
    • 免疫療法
    • 標的療法
  • 投与経路別
    • 注射
    • 経口
  • 薬剤クラス別
    • EGFR阻害薬
    • 有糸分裂阻害薬
    • 抗PD-1モノクローナル抗体
    • その他
  • 流通チャネル別
    • 小売店、専門薬局
    • 病院薬局
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 市場シェア：企業別（2023年）

第6章 世界の頭頸部がん市場の見通し：地域別（2017年～2031年）

  • 北米
    • 市場規模と予測
    • 治療タイプ別
    • 投与経路別
    • 薬剤クラス別
    • 流通チャネル別
    • 米国
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • メキシコ
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第7章 市場マッピング（2023年）

  • 治療タイプ別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第8章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析 - 数量と金額
  • サプライ/バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第9章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第10章 規制枠組みとイノベーション

  • 臨床試験
  • 特許情勢
  • 規制当局の承認
  • イノベーション/新技術

第11章 主要企業情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析（2023年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場参入企業5社）
  • 特許分析（該当する場合）

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Sanofi
  • Merck & Co., Inc.
  • Clinigen Group plc.
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • GlaxoSmithKline plc.

第15章 戦略的推奨事項

第16章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 4. Global Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 6. Global Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Head and Neck Cancer Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 11. North America Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 12. North America Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 13. North America Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Head and Neck Cancer Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 18. United States Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 19. United States Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 20. United States Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 24. Canada Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 25. Canada Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 26. Canada Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 30. Mexico Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 31. Mexico Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 32. Mexico Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 36. Europe Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 37. Europe Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 38. Europe Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Head and Neck Cancer Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 43. Germany Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44. Germany Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 45. Germany Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 49. France Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 50. France Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 51. France Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 55. Italy Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 56. Italy Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 57. Italy Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 61. United Kingdom Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 62. United Kingdom Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 63. United Kingdom Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 67. Russia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Russia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 69. Russia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 73. Netherlands Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 74. Netherlands Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 75. Netherlands Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 79. Spain Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80. Spain Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 81. Spain Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 85. Turkey Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86. Turkey Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 87. Turkey Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 91. Poland Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 92. Poland Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 93. Poland Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 97. South America Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 98. South America Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 99. South America Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Head and Neck Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 104. Brazil Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. Brazil Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 106. Brazil Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 110. Argentina Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 111. Argentina Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 112. Argentina Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 116. Asia-Pacific Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 117. Asia-Pacific Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 118. Asia-Pacific Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Head and Neck Cancer Market Share (%), By Country, 2017-2031F
  • Figure 120. India Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 123. India Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 124. India Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 125. India Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 129. China Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. China Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 131. China Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 135. Japan Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136. Japan Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 137. Japan Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 141. Australia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 142. Australia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 143. Australia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 147. Vietnam Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 148. Vietnam Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 149. Vietnam Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 153. South Korea Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 154. South Korea Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 155. South Korea Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 159. Indonesia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 160. Indonesia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 161. Indonesia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 165. Philippines Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166. Philippines Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 167. Philippines Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 171. Middle East & Africa Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172. Middle East & Africa Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 173. Middle East & Africa Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Head and Neck Cancer Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 178. Saudi Arabia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179. Saudi Arabia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 180. Saudi Arabia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 184. UAE Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 185. UAE Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 186. UAE Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 190. South Africa Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
  • Figure 191. South Africa Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
  • Figure 192. South Africa Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Therapy Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX10885

Global head and neck cancer market size was valued at USD 2.25 billion in 2023, and is expected to reach USD 3.76 billion in 2031, with a CAGR of 6.62% for the forecast period between 2024 and 2031F. The global head and neck cancer market encompasses a diverse range of treatments and therapies aimed at addressing the complex and challenging landscape of cancers that affect the head and neck regions. The market is experiencing significant growth and evolution as the understanding of the disease and its treatment options continue to advance.

Head and neck cancers, which include tumors in the oral cavity, pharynx, larynx, and other areas, represent a substantial global healthcare burden. Risk factors such as tobacco and alcohol consumption, human papillomavirus (HPV) infection, and environmental factors contribute to the development of these cancers. The global market for head and neck cancer is driven by factors such as increasing incidence rates, improved diagnostic methods, and the development of innovative therapeutic approaches. Recent advancements in immunotherapy and targeted therapies have brought hope to patients. These emerging treatment modalities, along with a growing focus on precision medicine and personalized treatment plans, are transforming the market. Key market players invest in research and development to introduce novel therapies and expand their product portfolios. Moreover, the increasing awareness about the importance of early detection and prevention contributes to market growth. The global head and neck cancer market is dynamic and rapidly evolving, focusing on improving patient outcomes through advanced treatment options and early intervention strategies.

Novel Therapies in Immunotherapy

As per an article published by Elsevier, it was reported that the introduction of immunotherapies has brought about a notable transformation in the treatment of head and neck cancer. These therapies are primarily focused on modulating the immunosuppressive pathways that mediate the interaction between tumor cells and T-lymphocytes. An article published in August 2022 by Frontiers highlighted the significant potential of immunotherapies to generate enduring antitumor effects, particularly in the context of treating head and neck squamous cell carcinomas. Various immunotherapy approaches, including the use of costimulatory agonists, immune checkpoint inhibitors, antigenic vaccines, adoptive T cell transfer (ACT), oncolytic virus therapy, and EGFR-targeted therapy, are now being employed for the management of head and neck squamous cell carcinomas (HNSCC). For Instance, Merck declared in November 2023 that the U.S. Food and Drug Administration (FDA) has given the green light to KEYTRUDA, Merck's anti-PD-1 therapy, along with gemcitabine and cisplatin, for addressing individuals dealing with locally advanced unresectable or metastatic biliary tract cancer (BTC).

Substantial Investment in Research and Development

In recent years, there has been a noticeable surge in research and development activities related to global head and neck cancer. The increased focus can be attributed to several factors, such as the rising incidence of head and neck cancer cases worldwide has spurred the need for more comprehensive research into prevention, early detection, and treatment strategies. Also, advancements in medical technologies, including genomics and targeted therapies, have opened new avenues for personalized and more effective treatments.

For instance, In October 2023, Nanobiotix, a biotechnology company in the later stages of clinical development, announced the initiation of patient enrollment for NANORAY-312, a phase III clinical trial to examine the safety and effectiveness of NBTXR3. The drug candidate has demonstrated significant promise in effectively treating head and neck cancer among elderly patients. In September 2022, Genexine Inc, a biotechnology company in the clinical stage focused on developing and marketing immunotherapies, announcing the initiation of patient dosing in a phase II clinical trial. The company employed a triple combination therapy involving GX-188E (a therapeutic DNA vaccine), GX-I7 (a long-acting interleukin 7), OpdivoR (nivolumab), and PD-1 immune checkpoint inhibitor, for addressing metastatic or recurrent head and neck squamous cell carcinoma.

Partnership and Acquisitions Between Key Market Players

In the dynamic landscape of global head and neck cancer market, strategic partnerships among key industry players have emerged as pivotal instruments for innovation and progress. These collaborations, characterized by shared expertise and resources, aim to advance research, develop cutting-edge therapies, and improve patient outcomes. Through such alliances, companies combine their strengths in drug development, medical technology, and clinical research to accelerate the discovery and delivery of novel treatments. These partnerships often foster synergies, allowing the pooling of knowledge, technologies, and financial resources. They facilitate the streamlining of regulatory processes and establishing wider access to global markets. Ultimately, these strategic alliances drive the evolution of more effective therapies, early detection methods, and personalized treatment solutions in the fight against head and neck cancers. The collective efforts of these collaborations hold promising potential for shaping the future of cancer care. For Instance, In November 2022, Fulgent Genetics, Inc., a technology-driven genetic testing company situated in the United States, revealed its acquisition of Fulgent Pharma Holdings, Inc. The acquisition aimed to offer a unified solution in the region's fight against head and neck cancer.

Strategic Initiatives by Key Players

Key players in the global head and neck cancer therapeutics market have been strategically focused on several initiatives to enhance treatment outcomes and address unmet medical needs. These initiatives primarily revolve around innovative research and development efforts, collaborative partnerships, and technological advancements. Companies are heavily investing in novel therapies, including immunotherapies and targeted therapies, to improve patient survival rates and reduce adverse effects. Additionally, these players are expanding their product portfolios through mergers, acquisitions, and licensing agreements to broaden their market presence and offer comprehensive solutions. They emphasize personalized medicine approaches, aiming to tailor treatments based on individual patient characteristics. For instance, in April 2023, Eisai initiated the "Made of More" initiative to foster a community for individuals affected by head and neck cancer. Additionally, Eisai is presently conducting trials combining its approved cancer medication, Lenvima, with other oncology drugs for treating head and neck cancers.

Impact of COVID-19

The head and neck cancer therapeutics market experienced significant disruption due to the COVID-19 pandemic. The health crisis particularly affected highly immunocompromised cancer patients, leading to strict lockdowns that hindered their access to essential treatments. Additionally, cancer screenings, preventive healthcare services, and elective surgeries were often delayed, except in cases where the benefits outweighed the risks and to prioritize hospital resources for COVID-19 care.

An article published by NCBI (National Center for Biotechnology Information) highlighted that elective surgeries, including head and neck cancer surgeries, were postponed in many countries. Approximately 60% of scheduled outpatient visits at the European Institute of Oncology (IEO) were delayed. The diversion of medical resources to attend COVID-19 patients resulted in a setback for head and neck cancer treatment, leading to increased tumor growth, recurrence, and high mortality rates. As a result, the COVID-19 pandemic significantly impacted the head and neck cancer diagnostics market.

Key Players Landscape and Outlook

With ongoing research and development, innovative treatments targeting PD-1/PD-L1 pathways have redefined the market. Additionally, companies are emerging with novel therapies, fostering a competitive market. The outlook is promising, emphasizing precision medicine, combination therapies, and biomarker research. Key players are intensifying efforts in clinical trials and strategic collaborations, underscoring a robust drive towards personalized and more effective treatments, potentially transforming the head and neck cancer market.

In August 2022, Genexine Inc, a clinical-stage biotech firm specializing in immunotherapeutics, announced the initiation of patient dosage in a phase II clinical trial. Employing a triple combination therapy comprising GX-188E (a therapeutic DNA vaccine), GX-I7 (a prolonged-acting interleukin 7), and OpdivoR (nivolumab), a PD-1 immune checkpoint inhibitor, the company aimed to treat metastatic head and neck squamous cell carcinoma.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Head and Neck Cancer Market

4. Executive Summary

5. Global Head and Neck Cancer Market Outlook, 2017-2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Therapy Type
    • 5.2.1. Chemotherapy
    • 5.2.2. Immunotherapy
    • 5.2.3. Targeted Therapy
  • 5.3. By Route of Administration
    • 5.3.1. Injectable
    • 5.3.2. Oral
  • 5.4. By Drug Class
    • 5.4.1. EGFR Inhibitors
    • 5.4.2. Mitotic Inhibitors
    • 5.4.3. Anti-PD-1 Monoclonal Antibodies
    • 5.4.4. Others
  • 5.5. By Distribution Channel
    • 5.5.1. Retail and Specialty Pharmacies
    • 5.5.2. Hospital Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. South America
    • 5.6.5. Middle East & Africa
  • 5.7. By Company Market Share (%), 2023

6. Global Head and Neck Cancer Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Therapy Type
      • 6.1.2.1. Chemotherapy
      • 6.1.2.2. Immunotherapy
      • 6.1.2.3. Targeted Therapy
    • 6.1.3. By Route of Administration
      • 6.1.3.1. Injectable
      • 6.1.3.2. Oral
    • 6.1.4. By Drug Class
      • 6.1.4.1. EGFR Inhibitors
      • 6.1.4.2. Mitotic Inhibitors
      • 6.1.4.3. Anti-PD-1 Monoclonal Antibodies
      • 6.1.4.4. Others
    • 6.1.5. By Distribution Channel
      • 6.1.5.1. Retail and Specialty Pharmacies
      • 6.1.5.2. Hospital Pharmacies
      • 6.1.5.3. Online Pharmacies
    • 6.1.6. United States*
      • 6.1.6.1. Market Size & Forecast
      • 6.1.6.1.1. By Value
      • 6.1.6.1.2. By Volume
      • 6.1.6.2. By Therapy Type
      • 6.1.6.2.1. Chemotherapy
      • 6.1.6.2.2. Immunotherapy
      • 6.1.6.2.3. Targeted Therapy
      • 6.1.6.3. By Route of Administration
      • 6.1.6.3.1. Injectable
      • 6.1.6.3.2. Oral
      • 6.1.6.4. By Drug Class
      • 6.1.6.4.1. EGFR Inhibitors
      • 6.1.6.4.2. Mitotic Inhibitors
      • 6.1.6.4.3. Anti-PD-1 Monoclonal Antibodies
      • 6.1.6.4.4. Others
      • 6.1.6.5. By Distribution Channel
      • 6.1.6.5.1. Retail and Specialty Pharmacies
      • 6.1.6.5.2. Hospital Pharmacies
      • 6.1.6.5.3. Online Pharmacies
      • 6.1.6.6. By Region
      • 6.1.6.6.1. North America
      • 6.1.6.6.2. Europe
      • 6.1.6.6.3. Asia-Pacific
      • 6.1.6.6.4. South America
      • 6.1.6.6.5. Middle East & Africa
      • 6.1.6.7. Canada
      • 6.1.6.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Mexico
    • 6.3.3. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Therapy Type
  • 7.2. By Route of Administration
  • 7.3. By Distribution Channel
  • 7.4. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. F. Hoffmann-La Roche Ltd.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Eli Lilly and Company
  • 14.3. Sanofi
  • 14.4. Merck & Co., Inc.
  • 14.5. Clinigen Group plc.
  • 14.6. Bristol-Myers Squibb Company
  • 14.7. AstraZeneca
  • 14.8. Takeda Pharmaceutical Company Limited
  • 14.9. Teva Pharmaceutical Industries Ltd
  • 14.10. GlaxoSmithKline plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer